Keith Harmon, MD
Pulmonary Disease · St Louis Park, MNNPI 1003892860
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Itamar Medical Inc accounts for 66.0% of it on its own, with 1 other manufacturer making up the rest. 2023 is the largest year on record at $34, 3.1 times the $11 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in MN, where the typical reported total is $128.
Across 4 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Itamar Medical Inc$46
- Philips North America LLC$23
What the payments were for
- Food & beverage$69100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Itamar Medical Inc | 2 | $46 |
| Philips North America LLC | 2 | $23 |
How this compares
$69 in reported general payments places this provider in the 40th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $499,797 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 331 | $253,915 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 189 | $109,362 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 132 | $71,896 |
| Breo ElliptaFluticasone/Vilanterol | 111 | $59,983 |
| Advair HfaFluticasone Propion/Salmeterol | 105 | $50,786 |
| Incruse ElliptaUmeclidinium Bromide | 77 | $38,800 |
| Spiriva RespimatTiotropium Bromide | 39 | $36,272 |
| Arnuity ElliptaFluticasone Furoate | 61 | $15,709 |
| Fluticasone Propionate HfaFluticasone Propionate | 31 | $14,357 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $12,812 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $9,252 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $8,781 |
| DuleraMometasone/Formoterol | 20 | $7,979 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,265 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in St Louis Park
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Jonathan HovdaMinneapolis$139K
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Hyun KimMinneapolis$77K
- Jagdeep BijwadiaRochester$54K
- Grady HedstromMinneapolis$50K
- Teng MouaRochester$47K
- Joseph KeenanMinneapolis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.